1,200
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Cut-off value for KLK3 gene expression from urine sediment to rationalize diagnosis of prostate cancer

, , , , , , & show all
Pages 18-23 | Received 29 Aug 2019, Accepted 17 Dec 2019, Published online: 26 Jan 2020

References

  • Rigau M, Olivan M, Garcia M, et al. The present and future of prostate cancer urine biomarkers. IJMS. 2013;14(6):12620–12649.
  • Mengual L, Lozano JL, Ingelmo-Torres M, et al. Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers. BMC Cancer.2016;16(1):76.
  • Oliveira JDD, Goulart LR, Oliveira WP, Jr, et al. DD3 gene expression in peripheral blood of patients with prostate cancer and with benign hyperplasia as a molecular diagnostic. Eur Urol Suppl. 2003;2(6):102.
  • Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44(1):8–15.
  • Leyten GHJM, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65(3):534–542.
  • Neves AF, Araújo TG, Biase WK, et al. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem. 2008;41(14–15):1191–1198.
  • Coelho FF, Guimarães FL, Cabral WL, et al. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer. Genet Mol Res. 2015;28(14(4):13519–13531.
  • Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550–560.
  • Rostad K, Mannelqvist M, Halvorsen OJ, et al. ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol. 2007;30(1):19–32.
  • Demichelis F, Setlur SR, Beroukhim R, et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosom Cancer. 2009;48(4):366–380.
  • Ponti G, Manfredini M, Tomasi A. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Crit Rev Oncol Hematol. 2019;141:36–42.
  • Larsen LK, Lind GE, Guldberg P, et al. DNA-methylation-based detection of urological cancer in urine: overview of biomarkers and considerations on biomarker design, source of DNA, and detection technologies. IJMS. 2019;20(11):2657.
  • Brikun I, Nusskern D, Freije D. An expanded biomarker panel for the detection of prostate cancer from urine DNA. Exp Hematol Oncol. 2019;8:13.